Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients (Q46447343)

From Wikidata

Jump to navigation Jump to search

scientific article published in May 2005

Language	Label	Description	Also known as
English	Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients	scientific article published in May 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

immunohistochemistry

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

author name string

Thiele J

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Kvasnicka HM

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Schmitt-Graeff A

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Kriener S

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Engels K

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Staib P

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Ollig ES

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Keller C

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Fokkema S

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Griesshammer M

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Waller CF

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Hansmann ML

13

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

46

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

540-550

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

STI571: targeting BCR-ABL as therapy for CML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Chronic myeloid leukemia: current treatment options

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Identification of apoptotic cells by formamide-induced dna denaturation in condensed chromatin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2005.02119.X

21 January 2018

Identifiers

10.1111/J.1365-2559.2005.02119.X

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15842636

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46447343&oldid=2112011865"